The effectiveness of use fertilovit mt drug in the treatment of men with reproductive dysfunction
Keywords:male infertility, pathospermia, lifestyle, Fertilovit MT
In Ukraine infertility affects about 20% of couples, and considering the very difficult economic and demographic situation this problem gets extremely negative value.
According to authors’ previous studies, in a barren marriage reproductive health disorders in men observed in 47.5% of cases. In the absence of diseases of the urogenital system the factors of steady decline in fertility are an unhealthy lifestyle, smoking, alcohol abuse, chronic fatigue, sleep deprivation and/or frequent stress, the combination of smoking with other negative factors, and abdominal obesity, which is largely a consequence of malnutrition. All these factors caused the limited level of pathospermia, and rarely – subfertile level of pathospermia.
The article contain the results of treatment with Fertilovit MT men with marked reduction of fertility which is not related with diseases of urogenital organs and any form of hypogonadism, but is a result of unhealthy lifestyle. The study involved 50 men, 74.0% of whom had the infertility from 1 to 4 years in the current marriage. 88.0% of patients have limited level of pathospermia, 12.0% – subfertile level of pathospermia. The average age of the patients was 34.2 ± 2.1 years.
All of men used Fertilovit MT from 1 capsule twice a day for 3 months. In addition, doctors urged recommend patients to give up bad habits and normalize their lifestyle.
After Fertilovit MT monotherapy within 3 months 80.0% of patients have improved semen parameters: sperm motility and concentration of sperms was increased, the number of degenerative forms was decreased. As a result of treatment 64.0% of men had reached a state of normozoospermia; at 36.0% of patients pathospermia was remained or reached limited level. Cases of violations of reproductive potential with subfertility level of pathospermia were not documented.
Thus, studies shown the high efficacy of Fertilovit MT in the treatment of men with mild disorders of the generative function, which are not caused by diseases of the genitourinary organs and any form of hypogonadism. The widespread use of the drug Fertilovit MT should be recommended for improve the fertility of patients with limited and subfertile levels of pathospermia, causes of whom are unknown or related to unhealthy lifestyles.
- Avramenko, N.V., Barkovskyi, D.E. “Reproductive health aspects of the Ukraine population.” Zaporizhzhya Medical Journal 3 (2010): 71–3.
- Bozhedomov, V.A., Rokhlikov, I.M., Tretyakov, A.A. “Andrology aspects of the organization help childless couples.” Kremlin medicine. Clinical herald 3 (2013):121–5.
- Galimov, Sh.N., Gromenko, D.S., Galimova, E.F., et al. “Effect of L-carnitine on the semen parameters of men from infertile couples.” Urology 1 (2012): 47–51.
- Vornik, B.M. “Sexuality and reproduction men in Ukraine: social and clinical parallels.” Health of male 3 (2012): 64–8.
- Gorpinchenko, I.I., Nikitin, O.D. “Barren marriage in Ukraine. The new realities.” Health of male 3 (2010): 184–90.
- Assisted reproductive technologies of infertility treatment. Tutorial. Ed. by prof. F.W. Dakhno, prof. V.V. Kaminskyi, prof. O.M. Yuzko. Kyiv (2011): 338 p.
- Kopkov, V.S., Tsanko, I.I. “Assisted reproductive technologies in solving of demographic problems. Legal Aspects.” Medical aspects of women health 4.68 (2013): 55–7.
- Povorozniuk, M.V. “The causes of reproductive health violation in men with infertility in marriage.” Health of male 2 (2015).
- Bozhedomov, V.A., Ushakova, I.V., Sporysh, E.A., et al. “The role of hyperproduction an active forms of oxygen in male infertility and antioxidant therapy opportunities (review of literature).” Consilium medicum 14/7 (2012): 51–6.
- Shamraev, S.N., Rutinskyi, A.I., Babiuk, I.A., Tsvetkova, P.D. “Modern conflicts of evaluation the condition of male semen.” Health of male 4 (2012): 19–23.
- Esteves, S.C., Sharma, R.K., Gosalvez, J., Agarwal, A. “A translational medicine appraisal of specialized andrology testing in unexplained male infertility.” Int Urol Nephrol 46.6 (2014): 1037–52.
- Agarwal, A., Tvrda, E., Sharma, R. “Relationship amongst teratozoospermia, seminal oxidative stress and male infertility.” Reprod Biol Endocrinol 12 (2014): 45.
- Naher, Z.U., Ali, M., Biswas, S.K., et al. “Effect of oxidative stress in male infertility.” Mymensingh Med J 22.1 (2013): 136–42.
- Farhi, J., Ben-Haroush, A. “Distribution of causes of infertility in patients attending primary fertility clinics in Israel.” Isr Med Assoc J 13.1 (2011): 51–4.
- Desai, N., Sabanegh, E. Jr., Kim, T., Agarwal, A. “Free radical theory of aging: implications in male infertility.” Urology 75.1 (2010): 14–9.
- Wang, Y., Yang, S., Qu, C., et al. “L-carnitine: safe and effective for asthenozoospermia.” Zhonghua Nan Ke Xue 6 (2010): 420–2.
- Durairajanayagam, D., Agarwal, A., Ong, C., Prashast, P. “Lycoptine and male infertility.” Asian J Androl 16.3 (2014): 420–5.
- Moyo, S. “Indigenous knowledge systems and attitudes towards male infertility in Mhondoro-Ngezi, Zimbabwe.” Cult Health Sex 15.6 (2013): 667–9.
- Niederberger, C.S. “The field of male infertility moves fast!” Urol Clin North Am 41.1 (2014): XVII.
- Nieschlag, E. “Male infertility: recent developments.“ Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56.12 (2013):1619–27.
- Ramya, T., Misro, M.M., Sinha, D., et al. “Sperm function and seminal oxidative stress as tools to identify sperm pathologies in infertile men.” Fertil Steril 93.1 (2010): 297–300.
How to Cite
Copyright (c) 2016 Е. Н. Борис, М. В. Поворознюк
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.